Celgene Corp. (CELG) - Bull of the Day

By
A A A

We are maintaining our Outperform recommendation on Celgene Corp. ( CELG ) following impressive preliminary results disclosed for the fourth quarter (adjusted EPS up 46%) and full year 2011 (adjusted EPS up 36%). Preliminary adjusted revenues in the final quarter of 2011 came in at $1.28 billion, 22% above the year-ago figure. For 2011, sales came in at $4.8 billion, up 34%.

The company also gave a bright outlook for 2012 with adjusted earnings expected to improve by 25%. We believe that Celgene, driven by its oncology portfolio and robust pipeline, should easily achieve the 2012 guidance. We believe that the current price represents an attractive entry point for long-term investors.

Based on 2012 P/E estimates, the stock is trading at 17.4x earnings, compared to the industry average of 28.1. Our target price of $87.00 per share is based on 20.8x our 2012 EPS estimate of $4.18.
 
CELGENE CORP ( CELG ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Investing Ideas , Stocks

Referenced Stocks: CELG

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Budgeting for Baby
Budgeting for Baby                  
A Home to Retire In
A Home to Retire In                 

Stocks

Referenced

Most Active by Volume

10,545,216
  • $17.0219 ▼ 0.16%
9,096,075
  • $13.74 ▼ 3.17%
8,973,171
  • $14.70 ▼ 0.61%
8,790,557
    $17.44 unch
7,581,720
  • $97.93 ▼ 0.87%
6,504,302
  • $99.85 ▼ 0.89%
6,387,608
  • $3.3801 ▲ 4.00%
6,196,615
  • $25.22 ▼ 1.56%
As of 10/1/2014, 10:00 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com